Our multidisciplinary team aims to provide care and support for patients and their families. Patients are routinely (every three months) seen by specialists in our team. Together with the NeuroCenter Network we coordinate medical, paramedical and social support at home for patients. We also take part in various research activities. These are directed to identify ALS risk genes, new biomarkers for diagnosis and prognosis, and clinical studies to develop suitable treatments. Finally, we are setting up an ALS Registry in the Center Val de Loire.
Contact
LocationCHU Bretonneau 2 Boulevard Tonnellé, 37044 Tours
Our Specialists
Current trials
Active
Phase ii
DAZALS trial
Industry trial
In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS (also known as MND) to understand its safety (side effects) and to determine if dazucorilant can slow down the worsening of the disease. The effects of dazucorilant will be compared to the effects of a placebo. This study is sponsored by Corcept Therapeutics.
Completed
Phase iii
PHOENIX trial
Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Completed
Phase iii
ADORE trial
Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Completed
Phase iii
TUDCA-ALS
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.